SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

ZNTL

ZENTALIS PHARMACEUTICALS
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · Regulatory
Actionable Insight • Neutral

This is a routine inducement grant with negligible dilution. No trading signal, monitor upcoming clinical catalysts for azenosertib (WEE1 inhibitor) in ovarian cancer for material moves.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.95
T+0 close · Jun 1, 2026 · via day close
Latest settled
−1.52%
T+60 · $3.89
Vs SPY
−2.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $3.95entry
  2. T+1 · 6mo ago −5.82%α −5.10% · $3.72
  3. T+5 · 5mo ago −9.37%α −6.40% · $3.58
  4. T+20 · 5mo ago +10.25%α +11.82% · $4.36
  5. T+60 · 3mo ago −1.52%α −2.64% · $3.89

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement for employment, with a $3.98 exercise price and four-year vesting. This is a routine equity inducement grant with no material financial impact.

Key Facts

  • 191,000 stock options granted to two new employees under the 2022 Inducement Plan
  • Exercise price of $3.98 per share, equal to the closing price on the grant date
  • Options vest over four years: 25% at first anniversary, then monthly over three years
  • Grant is an inducement material to employment per Nasdaq Listing Rule 5635(c)(4)

Financial Impact

191,000 options at $3.98 strike; dilution is immaterial relative to ~50M shares outstanding (est. <0.4%)

dilution

Risk Factors

  • No clinical or financial data disclosed; stock moves on pipeline events, not this grant

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304753

Track record

18 reports on ZNTL

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Viewing Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 8h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026